Damn the crit­ics, Bio­gen CEO Vounatsos or­ders full speed ahead on prep­ping a con­tro­ver­sial ad­u­canum­ab launch as FDA ...

5 years ago
Bioregnum
FDA+

In­vi­tae sets up shop in North Car­oli­na as part of plan to rapid­ly ex­pand its ge­net­ic test­ing man­u­fac­tur­ing

5 years ago
Manufacturing

Ver­tex adds a new gene edit­ing part­ner, pay­ing Ob­sid­i­an $75M for con­trol­lable CRISPR sys­tem

5 years ago
Deals

Ear­ly Zymer­gen in­vestor Jen­ny Rooke re­flects on 'chimeras' in biotech, what it takes to spot a $500M gem

5 years ago
People
Financing

Zymer­gen's bid to dis­rupt a $3T in­dus­tri­al man­u­fac­tur­ing mar­ket goes vi­ral, earn­ing a mas­sive $500M IPO

5 years ago
Financing
Manufacturing

Covid-19 roundup: Eu­ro­pean Com­mis­sion pre­pares to sue for As­traZeneca dos­es — re­port; NIH adds poly­clon­al an­ti­body ...

5 years ago
Coronavirus

Te­va CEO Kåre Schultz sees a 35% raise de­spite the com­pa­ny's con­tin­ued le­gal woes

5 years ago
People

Bris­tol My­ers finds a home for 1st EU cell ther­a­py site, clear­ing land near Am­s­ter­dam air­port for easy lo­gis­tics

5 years ago
Cell/Gene Tx
Manufacturing

On the heels of $250M launch, Centes­sa barges ahead with an IPO to fu­el its 10-in-1 Medicxi pipeline

5 years ago
Financing

An EU biotech looks to rewrite the ug­ly his­to­ry of phos­phatases, and it's tak­ing $24M in fund­ing to get off the ...

5 years ago
Financing

Law pro­fes­sors call for FDA to dis­close all safe­ty and ef­fi­ca­cy da­ta for drugs

5 years ago
Pharma
FDA+

Why re­mote drug man­u­fac­tur­ing eval­u­a­tions won't re­al­ly re­duce FDA's back­log of in­spec­tions

5 years ago
FDA+
Manufacturing

As fears mount over J&J and As­traZeneca, No­vavax en­ters a shaky spot­light

5 years ago
Coronavirus
In Focus

On the hunt for bugs out­side the gut, Seed Health snares $40M round to ad­vance pipeline with the help of George ...

5 years ago
Financing

No­vo Nordisk to launch PhI­II obe­si­ty tri­al for oral semaglu­tide; Edi­Gene ex­tends Se­ries B with ad­di­tion­al $62M

5 years ago
News Briefing

Pe­ter Thiel-backed ATAI is prepar­ing to go to Nas­daq, as in­ter­est in psy­che­delics reach­es fever pitch

5 years ago
Financing

FDA of­fers scathing re­view of Emer­gent plan­t's san­i­tary con­di­tions, em­ploy­ee train­ing af­ter halt­ing pro­duc­tion

5 years ago
FDA+

Covid-19 roundup: BioN­Tech ex­ec says new pro­duc­tion sites could be added to meet de­mand — re­port; Giv­ing up on the ...

5 years ago
Coronavirus

Alde­vron founders back a biotech start­up that's look­ing to end the moral de­bate over cell lines once and for all

5 years ago
Startups
Cell/Gene Tx

Roche sees a slight dip in Q1 as biosim­i­lars keep bit­ing in­to block­buster on­col­o­gy tri­o's sales

5 years ago
Pharma
Coronavirus

Bio­phar­ma ramps up lob­by­ing spend as drug pric­ing leg­is­la­tion nears

5 years ago
Pharma

Ex­clu­sive: Genen­tech's for­mer Tecen­triq 'CEO' jumps ship to head up com­mer­cial at an on­colyt­ic virus play­er

5 years ago
People

Ver­sant pulls the wraps off of near­ly $1B in 3 new funds out to build the next fleet of biotech star­tups. And this ...

5 years ago
Financing
Startups

House De­moc­rats call on Emer­gent ex­ecs to tes­ti­fy on qual­i­ty is­sues next month

5 years ago
Pharma
FDA+
First page Previous page 704705706707708709710 Next page Last page
A service from the Financial Times